DMAC vs MDT
DMAC: A clinical-stage biopharmaceutical company developing DM199, a recombinant human kallikrein-1 protein, to treat acute ischemic stroke, preeclampsia, and fetal growth restriction. MDT: Global medical device leader deploying pacemakers, defibrillators, spinal implants, surgical robotics, and diabetes management systems to alleviate pain, restore health, and extend life across 150+ countries.
Side-by-side fundamentals
| Metric | DMAC | MDT | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $6.93 | $81.89 | |
| Market cap as of 2026-07-23 | $376M | $105.1B | |
| P/E as of 2026-07-23 | n/a | 21.88 | |
| PEG as of 2026-07-23 | -1.09 | 2.90 | DMAC lower |
| Net margin as of 2026-07-23 | -1146.8% | +13.2% | MDT higher |
| Gross margin as of 2026-07-23 | n/a | +65.3% | |
| Operating margin as of 2026-07-23 | -1352.2% | +17.8% | MDT higher |
| ROE as of 2026-07-23 | -77.1% | +9.8% | MDT higher |
| ROA as of 2026-07-23 | -69.2% | +5.2% | MDT higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.57 | DMAC lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +8.4% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +5.2% | |
| Dividend yield as of 2026-07-23 | n/a | +3.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.97 | 0.57 | |
| 1-year return as of 2026-07-22 close | +55.9% | -10.6% | DMAC higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.